Free, source-traceable HIV knowledge
Menu
AIDS Research CenterEvidence for public health. Knowledge for everyone.
Privacy: no trackingAccessibility StatementSubmit a Correction
AIDS Research CenterEvidence for public health. Knowledge for everyone.SearchLanguageHelp
AIDS Research CenterEvidence for public health. Knowledge for everyone.
English
LanguageEnglishDeutschFrançaisEspañol
Accessibility
Display preferencesStored only on this device.
SavedGet Help

Opportunistic infections and advanced disease

Malignancies

Evidence-based indexes for conditions associated with advanced immune suppression.

Publisher
The Bach Foundation
Audience
Public · Professional · Research
Last reviewed
18 August 2026
Status
Source-linked
Jurisdiction
Global context; local guidance may vary

Essential answer

Malignancies is part of the Center’s opportunistic infections and advanced disease record.

Advanced immune suppression can increase vulnerability to specific infections and malignancies. Prevention, diagnosis and treatment depend on immune status, symptoms, geography and current guidance.

Complete public explanation

Evidence-based indexes for conditions associated with advanced immune suppression.

Use the information with its source date, population and jurisdiction. A general explanation cannot determine an individual’s diagnosis, eligibility, regimen or legal obligations.

Key considerations

  • Urgent symptoms require clinical assessment, not online self-diagnosis.
  • ART is central, but timing can interact with treatment of some opportunistic conditions.
  • Diagnostic availability and regional disease burden influence care pathways.
  • Prophylaxis and vaccination recommendations are context specific.

Research and evidence questions

01Which rapid diagnostics improve outcomes in low-resource settings?
02How should treatment timing balance immune recovery and inflammatory risk?
03Which prevention packages work at programme scale?
04How is regional epidemiology changing with treatment coverage?

Professional and academic evidence

Professional interpretation of malignancies adds study design, population, comparator, outcomes, statistical methods, limitations, conflicts, guideline adoption, geographic applicability, replication and integrity status.

Evidence record fields for Malignancies
FieldWhat the Center displays
Meaning and scopeDefinition, mechanism, intended use and what should not be inferred.
Population and jurisdictionAge, sex and gender, geography, HIV subtype, clinical context and issuing authority.
OutcomeClinical, virologic, diagnostic, public-health or implementation outcome and follow-up.
ProvenanceOriginal source, identifier, version, funding, conflicts, access date and review.
IntegrityProtocol changes, corrections, expressions of concern, retractions and later evidence.

Principal sources and evidence gateways

Links checked 18 August 2026
01
WHO updated recommendations on HIV clinical managementWorld Health Organization · Guideline · Access checked 18 Aug 2026
02
Clinical guidelines for HIV prevention and treatmentNIH Clinicalinfo · Guideline · Access checked 18 Aug 2026
03
Global HIV & AIDS statistics — 2025 reporting yearUNAIDS · Dataset · Access checked 18 Aug 2026
Additional permanent evidence gateways